Ivanovska Adjievska B, et al. – This study is performed to assess the 1–year effectiveness and safety of low–frequency intravitreal bevacizumab in the treatment of macular edema because of retinal vein occlusions (RVOs). In macular edema because of RVO, intravitreal bevacizumab provides an improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with the low number of injections.